‘ADVANCE’ (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer

Freedman, Rachel A.; Li, Tianyu; Sedrak, Mina S.; Hopkins, Judith O.; Tayob, Nabihah; Faggen, Meredith; Sinclair, Natalie; Chen, Wendy Y.; Parsons, Heather A.; Mayer, Erica L.; Lange, Paulina B.; Basta, Ameer S.; Perilla-Glen, Adriana; Lederman, Ruth I.; Wong, Andrew; Tiwari, Abhay; McAllister, Sandra S.; Mittendorf, Elizabeth A.; Miller, Peter; Gibson, Christopher J.; Burstein, Harold J.

doi:10.1016/j.jgo.2022.09.006

Cited by 5 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While avoidance of potentially toxic therapies is often appropriate in BC P80+ as risks may outweigh benefits, some older BC patients do benefit from adjuvant chemotherapy [14,15]. The ADVANCE (ADjuVANt Chemotherapy in the Elderly) trial assessed the feasibility of two (neo)adjuvant chemotherapy regimens in parallel-enrolling cohorts of older persons (≥ 70 years) with human epidermal growth factor receptor 2 (HER2)-negative BC [16]. Although neither regimen met target feasibility goals, trials such as ADVANCE inform the development of tolerable, evidence-based regimens for older BC patients who need chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years

O'Sullivan,

Vierkant,

Larson

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥ 80 years (P80+). Identifying and addressing unmet needs are critical. Aims: Advocate-BREAST80+ compared the needs of P80+ vs. patients < 80 years (P80-). Methods: In 12/2021, a REDCap survey was circulated electronically to 6,918 persons enrolled in the Mayo Clinic Breast Disease Registry. The survey asked about concerns and satisfaction with multiple aspects of BC care. Results: 2,437 participants responded (35 % response rate); 202 (8.3%) were P80+. P80+ were less likely to undergo local regional and systemic therapies vs. P80- (p

show abstract

Section: Discussionmentioning

confidence: 99%

Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years

O'Sullivan,

Vierkant,

Larson

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…15 In patients unfit for standard chemotherapy, a clinical trial with PEGylated-liposomal doxorubicin or low dose, oral metronomic cyclophosphamide plus methotrexate was never completed for poor accrual, and the overall therapeutic value of these nonstandard regimens remains largely unknown. 16 Alternative treatments with weekly schedules of paclitaxel and with the use of carboplatin in lieu of cyclophosphamide in TC-like regimens for older patients have recently been reported in the ADVANCE clinical trial, however with no clear better RDI 17 (Table 2).…”

Section: The Benefit Of Adjuvant Chemotherapy In Older Patients With Bcmentioning

confidence: 99%

Adjuvant Chemotherapy in Older Women With Early Breast Cancer

Trapani

2023

JCO

View full text Add to dashboard Cite

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice. The clinical discussion on the adjuvant chemotherapy in older patients with breast cancer (BC) should routinely include comprehensive considerations of the health implications of competitive comorbidities, the safety of the treatment itself, and the likelihood that an appropriate dose intensity will be received (ie, relative dose intensity > 85%). All these factors have prognostic implications, as recently confirmed in the secondary analysis of the Hurria Older PatiEnts clinical trial. Full-informed, shared decision making is essential to provide best care. Our clinical approach for women with BC age ≥ 65 years is based on a standardized screening for frailty, triggering comprehensive geriatric assessment, as appropriate. We only recommend evidence-based regimens that have showed to reduce the risk of cancer recurrence and potentially increase overall survival. We frequently prefer docetaxel-cyclophosphamide, for hormone receptor–positive BC, on the basis of the subgroup analysis of the USOR-9735 study in older population. We avoid single agents (eg, capecitabine or weekly docetaxel), as showed to be inferior treatments in the CALGB-49907 and ELDA trials, and modified nonstandard regimens, for the lack of strong evidence in support.

show abstract

In vitro antiproliferative effects of Vatairea macrocarpa (Benth.) Ducke lectin on human tumor cell lines and in vivo evaluation of its toxicity in Drosophila melanogaster

Costa,

Santos,

Barreto

et al. 2024

Food and Chemical Toxicology

View full text Add to dashboard Cite

‘ADVANCE’ (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer

Cited by 5 publications

References 63 publications

Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years

Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years

Adjuvant Chemotherapy in Older Women With Early Breast Cancer

In vitro antiproliferative effects of Vatairea macrocarpa (Benth.) Ducke lectin on human tumor cell lines and in vivo evaluation of its toxicity in Drosophila melanogaster

Contact Info

Product

Resources

About